Bnhof, G
GHK-Cu has been studied for managing matrix breakdown and replacement through matrix metalloproteinase activity
intermittent), duration, and the timing of consumption relative to other factors like meals or exercise
The comparator groups differed among studies, with some employing placebo controls (e.g., PIONEER-6, Gerstein 2019), others using active comparators such as sitagliptin, glimepiride, DPP-4 inhibitors, or SGLT2 inhibitors, and some utilizing standard care or intensive lifestyle interventions as the control
59 In that trial, 731 patients with HFpEF and BMI 30 kg/m 2 were randomised to receive tirzepatide or placebo for at least 52 weeks
Dermatology research and practice, 2020, 8547960